ClinicalTrials.gg
CompletedNCT01568398Updated Feb 10, 2014

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy

A Phase 3 interventional study of TAK-438 in Gastric Ulcer and Duodenal Ulcer, sponsored by Takeda. Completed at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.

Enrollment
10th of 10
27 · median 320
Started
2012
with 2 others
Phase 3
8 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
8 of 10
Takeda

Among the 10 studies testing vonoprazan in Stomach Ulcer, this one is the 10th largest by enrollment, is one of 3 that started in 2012, is one of 8 in phase 3, and was the 6th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Stomach Ulcer, or all of them as a file.
02

Study summary

The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term low-dose aspirin therapy will be investigated.

03

Conditions studied

  • Gastric Ulcer
  • Duodenal Ulcer

Keywords

  • Gastric or duodenal ulcer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who, in the opinion of the principal investigator or subinvestigator, are capable of understanding the details of the study and complying with them.
  2. Prior to study commencement, participants who are capable of signing and dating the information/consent form.
  3. Participants with a chronic disease (ischaemic cardiac disease, ischaemic cerebrovascular disease, etc.) which requires continuous low-dose aspirin oral therapy for prevention of thromboembolism during the treatment period.
  4. Participants who meet either 1 or 2 below according to gastric or duodenal endoscopy:

    • Ulcer scar (defined, in this study, as regenerative mucosa, convergence of mucosal fold, gastric wall transformation, etc) has been confirmed during endoscopy on the study drug initiation day (Visit 2).
    • Ulcer (mucosal defects of 3 mm or larger with white moss) or ulcer scar has been endoscopically confirmed before the study drug initiation day (Visit 2).
  5. Outpatient participants (inpatients for examinations are acceptable).
  6. Women with must agree to routinely take appropriate measures throughout treatment period, from giving consent to the study until 4 weeks after the final dose.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received treatment with another study drug (including approved drugs under post-marketing surveillance) within 84 days prior to commencement of screening
  2. Participants who have previously received TAK-438 in a clinical study or as a treatment
  3. Participants who are employees of institutions participating in this study and family members of such employees, participants in a dependent relationship with employees of institutions involved in conduct of the study (e.g., spouse, parent, child, sibling), and participants who are under duress in giving their consent
  4. Participant who have donated 400 mL or more of blood within 90 days prior to the commencement of screening
  5. Participants with a plan to change the type, dosage or administration of low-dose aspirin.
  6. Participants with ulcer (mucosal defects of 3 mm or larger with white moss) or active hemorrhage confirmed during gastric or duodenal endoscopy on the study drug initiation day (Visit 2)
  7. Participants with small intestinal hemorrhage, large intestinal hemorrhage, or gastrointestinal hemorrhage of unknown cause
  8. Participants with a history of surgery or scheduled surgery influencing gastric acid secretion (resection of upper gastrointestinal tract or vagotomy etc)
  9. Participants with a history or complication of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  10. Participants with a history or complication of aspirin asthma
  11. Participants who have a history of or allergy to TAK-438 (including its ) or aspirin or salicylic acid agents.
  12. Participants with current use of illicit drug or a history of drug abuse. and/or alcohol dependence within one year prior to the commencement of screening
  13. Participants who require treatment with prohibited concomitant drugs or therapies (see 7.3)
  14. Female participants who are pregnant or lactating; those who plan to become pregnant or donate ova during treatment period, from giving consent until 4 weeks after final dose
  15. Participants with serious central nervous system disorders, cardiovascular disease, pulmonary disease, hepatic disease, renal disease, metabolic disease, gastrointestinal disorders, urinary disorders, endocrine disease, or blood dyscrasia
  16. Participants who plan to undergo surgery requiring hospitalization or requires surgery during the study period
  17. Participants with a history of a (or treatment thereof) within 5 years prior to the commencement of screening; however, participants with completely cured of basal cell carcinoma of skin or carcinoma in situ of the cervix may be included in the study.
  18. Participants with acquired immune deficiency syndrome (AIDS; including carriers) or hepatitis (including viral hepatitis carriers [HBs antigen positive or antibody positive]); however, Participants who are hepatitis C virus (HCV) antigen negative or HCV-RNA negative may be included in the study.
  19. Participants who meet either of the following laboratory test values at the beginning of screening (Visit 1)

    • Serum creatinine value: higher than 2 mg/dL
    • (ALT) or aspartate aminotransferase (AST): higher than 2.5 × the
    • Total : higher than 2.0 × the upper limit of normal
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
27 participants (actual)

Study arms

  • Experimental
    TAK-438 20 mg QD

    Drug: TAK-438

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Time frame: 24 weeks

07

Study locations

19 sites
  • Funabashi-shi, Chiba, Japan
  • Noda-shi, Chiba, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Annaka-shi, Gunma, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Hakodate-shi, Hokkaido, Japan
  • Kitahiroshima-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Yubari-gun, Hokkaido, Japan
  • Kanazawa-shi, Ishikawa, Japan
  • Sanuki-shi, Kagawa, Japan
  • Sendai-shi, Miyagi, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Sasebo-shi, Nagasaki, Japan
  • Fuchu-shi, Tokyo, Japan
  • Katsushika-ku, Tokyo, Japan
  • Meguro-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Nakano-ku, Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2012
First posted
Apr 2, 2012
Start
May 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01568398
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
May 2012
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Feb 10, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion